Evaluation of long-term efficacy outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response.
Medical records of patients that previously underwent the Alpha DaRT treatment will be reviewed by an authorized staff member. Evaluation of long-term outcomes of patients previously treated with the Alpha DaRT seeds for management of their malignancy following initial response. These outcomes include: * Safety - assessment of late onset of Alpha DaRT related AE in patients treated with the Alpha DaRT seeds * Efficacy - * assessment of local recurrence rates in patients who achieved initial complete response (CR) following the Alpha DaRT treatment * assessment of duration of response in patients who achieved initial CR following the Alpha DaRT treatment * assessment of survival status in patients treated with the Alpha DaRT seeds
Study Type
OBSERVATIONAL
Enrollment
33
Davidof Cancer Institution at the Rabin Medical Center Israel
Petah Tikva, Israel
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
Meldola, Italy
Progression Free Survival (PFS)
Time from DaRT insertion to disease progression (according to RECIST V1.1) or death, whichever occurs first
Time frame: Up to 60 months following DaRT insertion
Adverse Events (AE)
Assessment of late onset of Alpha DaRT related AE
Time frame: Up to 60 months following DaRT insertion
Duration of Response
Time from partial or complete response to the first disease progression according to RECIST V1.1
Time frame: Up to 60 months following DaRT insertion
Overall Survival (OS)
Time from DaRT insertion to death
Time frame: Up to 60 months following DaRT insertion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.